Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-10 1:15 pm Purchase | 2025-12-31 | 13G | Precision BioSciences, Inc. DTIL | Octagon Capital Advisors LP | 2,328,485 9.990% | 2,328,485 (New Position) | Filing History |
| 2026-02-10 1:15 pm Unchanged | 2025-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY | Octagon Capital Advisors LP | 1,000,000 4.700% | 0 (Unchanged) | Filing History |
| 2026-02-10 1:14 pm Sale | 2025-12-31 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Octagon Capital Advisors LP | 955,000 5.400% | -160,000 (-14.35%) | Filing History |
| 2026-02-10 1:13 pm Purchase | 2025-12-31 | 13G | Palisade Bio, Inc. PALI | Octagon Capital Advisors LP | 9,567,898 6.400% | 9,567,898 (New Position) | Filing History |
| 2025-11-14 4:46 pm Sale | 2025-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Octagon Capital Advisors LP | 1,971,054 4.900% | -5,333 (-0.27%) | Filing History |
| 2025-11-14 4:46 pm Purchase | 2025-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 2,416,667 6.100% | 306,500 (+14.52%) | Filing History |
| 2025-11-14 4:46 pm Sale | 2025-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA | Octagon Capital Advisors LP | 9,067,500 3.300% | -1,382,500 (-13.23%) | Filing History |
| 2025-11-14 4:46 pm Unchanged | 2025-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | Octagon Capital Advisors LP | 1,000,000 5.700% | 0 (Unchanged) | Filing History |
| 2025-08-12 4:05 pm Purchase | 2025-06-30 | 13G | Unicycive Therapeutics, Inc. UNCY | Octagon Capital Advisors LP | 1,000,000 7.800% | 1,000,000 (New Position) | Filing History |
| 2025-02-05 6:28 pm Purchase | 2024-12-31 | 13G | Gossamer Bio, Inc. GOSS | Octagon Capital Advisors LP | 19,576,054 8.600% | 19,576,054 (New Position) | Filing History |
| 2025-02-05 6:05 pm Purchase | 2024-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | Octagon Capital Advisors LP | 10,450,000 5.100% | 10,450,000 (New Position) | Filing History |
| 2025-02-05 5:42 pm Purchase | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 2,110,167 7.100% | 363,500 (+20.81%) | Filing History |
| 2024-10-28 4:03 pm Purchase | 2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR | Octagon Capital Advisors LP | 225,000 1.800% | 225,000 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | AlloVir, Inc. ALVR | Octagon Capital Advisors LP | 487,043 9.700% | 487,043 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | ArriVent BioPharma, Inc. Common Stock AVBP | Octagon Capital Advisors LP | 1,976,387 5.900% | 1,976,387 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | Octagon Capital Advisors LP | 1,115,000 9.300% | 1,115,000 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Dianthus Therapeutics, Inc. DNTH | Octagon Capital Advisors LP | 1,746,667 6.000% | 1,746,667 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Regulus Therapeutics Inc. RGLS | Octagon Capital Advisors LP | 4,263,701 6.500% | 4,263,701 (New Position) | Filing History |
| 2024-10-11 4:02 pm Purchase | 2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | Octagon Capital Advisors LP | 855,900 9.100% | 855,900 (New Position) | Filing History |
| 2024-08-28 4:02 pm Sale | 2024-08-26 | 13G | AN2 Therapeutics, Inc. ANTX | Octagon Capital Advisors LP | 0 0.000% | -3,009,927 (Position Closed) | Filing History |